Paul Sugarbaker

Summary

Country: USA

Publications

  1. ncbi Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non-gynecologic cancer
    Konstantinos M Stamou
    Washington Cancer Institute, Washington Hospital Center, NW, Washington, DC 20010, USA
    J Surg Oncol 83:197-203. 2003
  2. ncbi Management of peritoneal surface malignancy. Preface
    Paul H Sugarbaker
    Surg Oncol Clin N Am 12:xxi-xxiv. 2003
  3. ncbi Re: Verwaal VJ, van Tinteren H, Ruth SV, et al.: Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004; 85:61-67
    Paul H Sugarbaker
    J Surg Oncol 88:276-8. 2004
  4. ncbi Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy
    Tristan D Yan
    Program in Peritoneal Surface Malignancy, Department of Surgical Oncology, Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
    Cancer 103:839-49. 2005
  5. ncbi New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?
    Paul H Sugarbaker
    Washington Cancer Institute, 106 Irving Street, NW Suite 3900 Washington, DC 20020, USA
    Lancet Oncol 7:69-76. 2006
  6. doi Colorectal cancer metastases: a surgical perspective
    Paul H Sugarbaker
    Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
    Surg Oncol Clin N Am 22:289-98. 2013
  7. doi Early intervention for treatment and prevention of colorectal carcinomatosis: a plan for individualized care
    Paul H Sugarbaker
    Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, DC 20010, USA
    Surg Oncol Clin N Am 21:689-703. 2012
  8. doi Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach?
    Paul H Sugarbaker
    Washington Cancer Institute, Washington, DC, USA
    Lancet Oncol 13:e362-9. 2012
  9. doi Parietal peritonectomy
    Paul H Sugarbaker
    Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA
    Ann Surg Oncol 19:1250. 2012
  10. pmc Management of appendiceal pseudomyxoma peritonei diagnosed during pregnancy
    Erika Haase
    Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia, USA
    World J Surg Oncol 7:48. 2009

Collaborators

Detail Information

Publications95

  1. ncbi Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non-gynecologic cancer
    Konstantinos M Stamou
    Washington Cancer Institute, Washington Hospital Center, NW, Washington, DC 20010, USA
    J Surg Oncol 83:197-203. 2003
    ..Historic controls of surgical efforts report high postoperative mortality and morbidity rates with equivocal palliation. Novel surgical procedures need to be tested in terms of the impact on survival and quality of life...
  2. ncbi Management of peritoneal surface malignancy. Preface
    Paul H Sugarbaker
    Surg Oncol Clin N Am 12:xxi-xxiv. 2003
  3. ncbi Re: Verwaal VJ, van Tinteren H, Ruth SV, et al.: Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 2004; 85:61-67
    Paul H Sugarbaker
    J Surg Oncol 88:276-8. 2004
  4. ncbi Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy
    Tristan D Yan
    Program in Peritoneal Surface Malignancy, Department of Surgical Oncology, Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
    Cancer 103:839-49. 2005
    ..The aim of the current study was to identify computed tomography (CT) scan images that are useful in patient selection for this comprehensive approach...
  5. ncbi New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?
    Paul H Sugarbaker
    Washington Cancer Institute, 106 Irving Street, NW Suite 3900 Washington, DC 20020, USA
    Lancet Oncol 7:69-76. 2006
    ..In the absence of a phase III study, this new combined treatment should be regarded as the standard of care for epithelial appendiceal neoplasms and pseudomyxoma peritonei syndrome...
  6. doi Colorectal cancer metastases: a surgical perspective
    Paul H Sugarbaker
    Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
    Surg Oncol Clin N Am 22:289-98. 2013
    ..Formulation of an individualized plan combining surgery with regional chemotherapy and systemic chemotherapy is a necessary function of the multidisciplinary team...
  7. doi Early intervention for treatment and prevention of colorectal carcinomatosis: a plan for individualized care
    Paul H Sugarbaker
    Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, DC 20010, USA
    Surg Oncol Clin N Am 21:689-703. 2012
    ..Alternatively, the use of hyperthermic intraperitoneal chemotherapy can be used to treat or prevent carcinomatosis at the time of primary colorectal cancer resection in selected patients...
  8. doi Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach?
    Paul H Sugarbaker
    Washington Cancer Institute, Washington, DC, USA
    Lancet Oncol 13:e362-9. 2012
    ..Whether randomised, controlled trials are needed to definitively show the magnitude of benefit, if any, of this approach is an important question. This Debate outlines the arguments on each side of this issue...
  9. doi Parietal peritonectomy
    Paul H Sugarbaker
    Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA
    Ann Surg Oncol 19:1250. 2012
    ..Generally, the parietal peritonectomy takes approximately 2½ h and does not require blood replacement. After the parietal peritonectomy, additional cytoreductive surgical procedures and then perioperative chemotherapy are performed...
  10. pmc Management of appendiceal pseudomyxoma peritonei diagnosed during pregnancy
    Erika Haase
    Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia, USA
    World J Surg Oncol 7:48. 2009
    ..Epithelial tumors of the appendix on the other hand are rare and account for only approximately 1% of all colorectal neoplasms; the occurrence of this neoplasm during pregnancy is extremely rare...
  11. pmc Interstitial pneumonitis following intrapleural chemotherapy
    Luis Zappa
    Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, DC, USA
    World J Surg Oncol 7:17. 2009
    ..Treatment of this condition is by parietal and visceral pleurectomy followed by hyperthermic intrapleural chemotherapy...
  12. pmc Bologna Guidelines for Diagnosis and Management of Adhesive Small Bowel Obstruction (ASBO): 2010 Evidence-Based Guidelines of the World Society of Emergency Surgery
    Fausto Catena
    Emergency Surgery Unit, Department of General and Multivisceral Transplant Surgery, S, Orsola Malpighi University Hospital, Bologna, Italy
    World J Emerg Surg 6:5. 2011
    ..abstract:..
  13. pmc Guidelenines in the management of obstructing cancer of the left colon: consensus conference of the world society of emergency surgery (WSES) and peritoneum and surgery (PnS) society
    Luca Ansaloni
    1st Unit of General Surgery, Ospedali Riuniti di Bergamo, Italy
    World J Emerg Surg 5:29. 2010
    ..abstract:..
  14. ncbi Adjuvant intraperitoneal chemotherapy for advanced primary gastric cancer
    P H Sugarbaker
    Washington Cancer Institute, 106 Irving St, NW, Suite 3900, Washington, DC 20010, USA
    Scand J Surg 95:270-3. 2006
    ..Also, cancer dissemination caused from the trauma of cancer resection can release viable cancer cells into the free peritoneal cavity; these cells implant and then progress as peritoneal carcinomatosis...
  15. ncbi Comprehensive management of diffuse malignant peritoneal mesothelioma
    P H Sugarbaker
    Program in Peritoneal Surface Oncology, Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA
    Eur J Surg Oncol 32:686-91. 2006
    ..The length of the survival was dependent upon the aggressive versus indolent biology of the neoplasm, nevertheless cure was not considered as a reasonable expectation and the overall median survival was approximately one year...
  16. ncbi The natural history, gross pathology, and histopathology of appendiceal epithelial neoplasms
    P H Sugarbaker
    Washington Cancer Institute, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA
    Eur J Surg Oncol 32:644-7. 2006
    ..To report the pathology of appendiceal epithelial neoplasms a review of the Washington Cancer Institute experience and a PubMed literature search was performed...
  17. ncbi Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy
    Paul H Sugarbaker
    Washington Cancer Institute, 106 Irving Street, N W, Suite 3900, Washington, DC 20010, USA
    Ann Surg Oncol 13:635-44. 2006
    ..Patients with these diagnoses were treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy...
  18. ncbi The approval process for hyperthermic intraoperative intraperitoneal chemotherapy
    P H Sugarbaker
    Washington Cancer Institute, Washington Hospital Center, 106 Irving St, NW, Suite 3900, Washington, DC 20010, USA
    Eur J Surg Oncol 32:637-43. 2006
    ..To clarify the requirements for Food and Drug Administration approval in the United States for hyperthermic intraoperative intraperitoneal chemotherapy administration. Also, to review the status of the approval process in Europe...
  19. ncbi Hybrid ileostomy
    Paul H Sugarbaker
    Washington Cancer Institute, Washington, District of Columbia 20010, USA
    J Surg Oncol 93:161-3. 2006
  20. ncbi A curative approach to peritoneal carcinomatosis from colorectal cancer
    Paul H Sugarbaker
    Washington Cancer Institute, Washington, DC 20010, USA
    Semin Oncol 32:S68-73. 2005
    ..Because these combined treatment modalities have been investigated in large numbers of patients, the selection factors for acceptable long-term survival combined with a well-defined morbidity and mortality have become established...
  21. ncbi Strategies for management of the peritoneal surface component of cancer: cytoreductive surgery plus perioperative intraperitoneal chemotherapy
    Paul H Sugarbaker
    Washington Cancer Institute, Washington, DC 20010, USA
    J Oncol Pharm Pract 11:111-9. 2005
    ..A prominent part of treatment failure of gastrointestinal and gynecologic malignancy is dissemination to peritoneal surfaces. This has been associated with a limited survival and no reliable treatment strategies...
  22. ncbi An instrument to provide containment of intraoperative intraperitoneal chemotherapy with optimized distribution
    Paul H Sugarbaker
    Washington Cancer Institute, Washington, DC 20010, USA
    J Surg Oncol 92:142-6. 2005
  23. ncbi Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C
    Paul H Sugarbaker
    Program in Peritoneal Surface Malignancy, Washington Cancer Institute, 106 Irving st NW, POB 3900, Washington DC, 20010, USA
    Cancer Chemother Pharmacol 57:703-8. 2006
    ..While optimizing the use of this treatment strategy, little information regarding the effect of volume of chemotherapy solution is available...
  24. ncbi Peritoneal surface oncology: review of a personal experience with colorectal and appendiceal malignancy
    P H Sugarbaker
    Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA
    Tech Coloproctol 9:95-103. 2005
    ..Additional adjuvant phase III studies with perioperative intraperitoneal chemotherapy in diseases where peritoneal surface spread occurs are indicated...
  25. ncbi Peritonectomy procedures
    P H Sugarbaker
    Washington Cancer Institute, Washington, DC 20010, USA
    Cancer Treat Res 134:247-64. 2007
  26. ncbi Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy
    P H Sugarbaker
    Washington Cancer Institute, Washington, DC 20010, USA
    Int J Hyperthermia 23:431-42. 2007
    ..Much work needs to be done to identify a proper clinical perspective on hyperthermia used with chemotherapy in patients with peritoneal surface malignancy...
  27. doi Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis
    P H Sugarbaker
    Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900, Washington, DC 20010, USA
    Eur J Surg Oncol 37:719-26. 2011
    ..Doxorubicin is a drug consistently used by our group in this clinical setting. The surgical and clinical factors that modify the pharmacokinetics of HIPEC may be important for the design of future perioperative chemotherapy regimens...
  28. doi Revised guidelines for second-look surgery in patients with colon and rectal cancer
    Paul H Sugarbaker
    Washington Cancer Institute, Washington, DC 20010, USA
    Clin Transl Oncol 12:621-8. 2010
    ..A new management plan utilized in patients at high risk for local-regional recurrence may result in a high likelihood of conversion of a second-look cancer-positive patient to a long-term survivor...
  29. doi Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin
    Paul H Sugarbaker
    Washington Cancer Institute, Washington, DC 20010, USA
    J Surg Oncol 102:576-81. 2010
    ..Also, these patients are recommended for systemic chemotherapy using an oxaliplatin and 5-fluorouracil (FOLFOX) regimen. A major question concerns the proper timing (neoadjuvant vs. adjuvant) of the systemic chemotherapy...
  30. doi Surgical responsibilities in the management of peritoneal carcinomatosis
    Paul H Sugarbaker
    The Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia 20010, USA
    J Surg Oncol 101:713-24. 2010
    ..Carcinomatosis can be prevented and can be successfully treated using cytoreductive surgery and perioperative chemotherapy...
  31. doi Pont hepatique (hepatic bridge), an important anatomic structure in cytoreductive surgery
    Paul H Sugarbaker
    Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia 20010, USA
    J Surg Oncol 101:251-2. 2010
    ..Cancer dissemination on peritoneal surfaces can be treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. To maximize benefits a complete cancer removal precedes the chemotherapy treatments...
  32. doi Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach
    Paul H Sugarbaker
    Washington Cancer Institute, 106 Irving Street, NW, Suite 3900N, Washington, DC 20010, USA
    Expert Opin Pharmacother 10:1965-77. 2009
    ..Multiple reports to date document marked survival benefits; a previously lethal condition can be cured in selected patients. Further pharmacologic research and more knowledgeable patient selection for treatment are required...
  33. doi Epithelial appendiceal neoplasms
    Paul H Sugarbaker
    Program in Peritoneal Surface Malignancy, Washington Cancer Institute, 106 Irving Street, NW, Suite 3900, WA, DC 20010, USA
    Cancer J 15:225-35. 2009
    ..The presence versus absence of lymph nodal metastases on survival have minimal significance (P = 0.0495). These results of treatment can be achieved with a 19% incidence of severe complications and a 2% mortality...
  34. doi Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer
    Paul H Sugarbaker
    Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, District of Columbia 20010, USA
    Curr Opin Obstet Gynecol 21:15-24. 2009
    ..The conventional treatment approach for advanced ovarian malignancy is surgical debulking and systemic chemotherapy. More than 50% of these patients relapse within 5 years...
  35. ncbi Management of mucinous urachal neoplasm presenting as pseudomyxoma peritonei
    Paul H Sugarbaker
    Washington Cancer Institute, Washington, DC 20010, USA
    Tumori 94:732-6. 2008
    ..Mucinous neoplasms of the urachus are rare malignancies so that the physicians' index of suspicion for a timely and accurate diagnosis is low. Also, this disease may present with a wide variety of symptoms and signs...
  36. ncbi The porta hepatis as a site of recurrence of mucinous appendiceal neoplasms treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy
    Paul H Sugarbaker
    Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington DC, USA
    Tumori 94:694-700. 2008
    ..The goal of this study was to investigate the porta hepatis as a site of recurrence of appendiceal mucinous neoplasms...
  37. doi Circumferential cutaneous traction for exposure of the layers of the abdominal wall
    Paul H Sugarbaker
    Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
    J Surg Oncol 98:472-5. 2008
    ..Clear exposure of the operative field at all stages of a surgical procedure is a requirement of an optimal intervention. Current techniques for retraction do not provide visualization of the abdominal wall...
  38. ncbi Thin-walled cysts as a pathognomonic CT finding in cystic mesothelioma
    Paul Sugarbaker
    Washington Cancer Institute, Washington, DC 20010, USA
    Tumori 94:14-8. 2008
    ..Cystic mesothelioma is a rare disease that results in abdominal distention and poorly defined abdominal pain. Diagnosis has always been made by tissue biopsy rather than by radiologic studies...
  39. ncbi Colorectal carcinomatosis: a new oncologic frontier
    Paul H Sugarbaker
    Washington Cancer Institute, Washington Hospital Center, DC 20010, USA
    Curr Opin Oncol 17:397-9. 2005
    ..In the past, carcinomatosis from colorectal cancer was determined to be a lethal condition with a short survival...
  40. ncbi Strategies for the prevention and treatment of peritoneal carcinomatosis from gastrointestinal cancer
    Paul H Sugarbaker
    Washington Cancer Institute, Washington, District of Columbia 20010, USA
    Cancer Invest 23:155-72. 2005
    ..In the past, this clinical situation was treated only with palliative intent...
  41. ncbi Pedunculated peritoneal surface polyps in pseudomyxoma peritonei syndrome
    P H Sugarbaker
    The Washington Cancer Institute, Washington, DC 20010, USA
    Histopathology 39:525-8. 2001
    ..The purpose of this study was to examine the mechanism whereby the small bowel remains free of gross tumour and peritoneal surface polyps form...
  42. ncbi Peritonectomy procedures
    Paul H Sugarbaker
    Program in Peritoneal Surface Malignancy, Washington Cancer Institute, 100 Irving St, NW, Suite CG 185, Washington, DC 20010, USA
    Surg Oncol Clin N Am 12:703-27, xiii. 2003
    ..Several different procedures are required in a single surgical event that may require 8-12 hours. Their use depends on the distribution and extent of invasion of the malignancy disseminated within the peritoneal space...
  43. ncbi Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer
    Paul H Sugarbaker
    Washington Cancer Institute, Washington, DC, USA
    Semin Surg Oncol 21:233-48. 2003
    ..Sufficient data are available from the gastric cancer literature to support the use of these combined treatments on a routine basis if the primary cancer is resectable and gastrointestinal function can be reestablished...
  44. ncbi A review of peritoneal mesothelioma at the Washington Cancer Institute
    Paul H Sugarbaker
    Program in Peritoneal Surface Malignancy, Washington Cancer Institute, 110 Irving St, NW, Washington, DC 20010, USA
    Surg Oncol Clin N Am 12:605-21, xi. 2003
    ..Female patients had a significantly better prognosis than males. The other significant predictive factors of survival were: age, diagnosis by incidental findings, tumor extent, pathology, and completeness of cytoreduction...
  45. ncbi Transureteroureterostomy: an adjunct to the management of advanced primary and recurrent pelvic malignancy
    Paul H Sugarbaker
    Washington Cancer Institute, 110 Irving St NW, Washington, DC 20010, USA
    Int J Colorectal Dis 18:40-4. 2003
    ..With unilateral involvement, reconstruction of the ureters with salvage of the ipsilateral renal function should be considered...
  46. ncbi Managing the peritoneal surface component of gastrointestinal cancer. Part 1. Patterns of dissemination and treatment options
    Paul H Sugarbaker
    Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, DC, USA
    Oncology (Williston Park) 18:51-9. 2004
    ..The results of combined treatment as they vary in mucinous and nonmucinous tumors are also discussed...
  47. ncbi The subpyloric space: an important surgical and radiologic feature in pseudomyxoma peritonei
    P H Sugarbaker
    The Washington Cancer Institute, Washington, D C 20010, USA
    Eur J Surg Oncol 28:443-6. 2002
    ..In some patients mucinous tumour that surrounds the stomach is an important consideration in accomplishing a complete cytoreduction...
  48. ncbi Cytoreduction including total gastrectomy for pseudomyxoma peritonei
    P H Sugarbaker
    Washington Cancer Institute, 110 Irving Street NW, Washington, DC 20010, USA
    Br J Surg 89:208-12. 2002
    ..In some patients, the stomach and/or its vascular supply are so covered by mucinous tumour that total gastrectomy is required for complete resection...
  49. ncbi Central venous access through the right gonadal vein
    Paul H Sugarbaker
    Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
    J Surg Oncol 79:71. 2002
  50. ncbi Carcinomatosis from gastrointestinal cancer
    Paul H Sugarbaker
    Washington Cancer Institute, Washington, DC 20010, USA
    Ann Med 36:9-22. 2004
    ..One may conclude that selected patients with carcinomatosis should expect longterm survival with a combined treatment approach using cytoreductive surgery with perioperative intraperitoneal chemotherapy...
  51. ncbi Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy
    Paul H Sugarbaker
    Program in Peritoneal Surface Malignancy, Washington Cancer Institute, 110 Irving St, NW Washington, DC 20010, USA
    Oncologist 10:112-22. 2005
    ..Innovative treatment strategies can improve the outcome of patients with peritoneal surface malignancy...
  52. ncbi Avoiding carcinogen exposure with intraperitoneal paclitaxel
    Oswald A Stuart
    Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA
    Oncol Nurs Forum 32:44-8. 2005
    ..Previous studies have documented the leaching of DEHP from PVC-based containers and extension sets during the IV administration of paclitaxel...
  53. ncbi Managing the peritoneal surface component of gastrointestinal cancer. Part 2. Perioperative intraperitoneal chemotherapy
    Paul H Sugarbaker
    Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington, DC, USA
    Oncology (Williston Park) 18:207-19; discussion 220-2, 227-8, 230. 2004
    ..The results of combined treatment as they vary in mucinous and nonmucinous tumors are also discussed...
  54. ncbi Failure analysis of recurrent disease following complete cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer
    Lana Bijelic
    Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA
    Ann Surg Oncol 14:2281-8. 2007
    ..The aim of this study was to analyze the anatomic distribution, timing, and outcomes of recurrent disease after complete cytoreduction and perioperative intraperitoneal chemotherapy (PIC) for peritoneal carcinomatosis of colorectal origin...
  55. ncbi Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer
    Rodrigo Gomes da Silva
    Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
    J Am Coll Surg 203:878-86. 2006
    ..Proper selection factors are important because palliative surgery in these patients has not proved beneficial...
  56. ncbi Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms
    Tristan D Yan
    Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, 106 Irving Street NW, Suite 3900N, Washington, DC 20010, USA
    Ann Surg Oncol 14:2289-99. 2007
    ..The objective of this data analysis was to study treatment failure after complete cytoreduction for peritoneal dissemination from appendiceal mucinous neoplasms...
  57. ncbi Third look surgery and beyond for appendiceal malignancy with peritoneal dissemination
    Faheez Mohamed
    The Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
    J Surg Oncol 83:5-12; discussion 12-3. 2003
    ..Second look surgery has been previously studied in patients with recurrent peritoneal dissemination from appendiceal malignancy. However, selection criteria for third, fourth, and subsequent reoperations are not available...
  58. ncbi Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics
    Vinicius de Lima Vazquez
    Washington Cancer Institute, Washington DC, USA
    Cancer Chemother Pharmacol 52:108-12. 2003
    ..To measure the clearance intraperitoneal mitomycin C and doxorubicin in patients having peritonectomy and analyze the impact of the extent of peritoneal resection on pharmacokinetics...
  59. ncbi Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma
    Tristan D Yan
    Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington, DC, USA
    J Clin Oncol 24:4011-9. 2006
    ..The efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for patients with peritoneal carcinomatosis from colorectal carcinoma remains to be established...
  60. ncbi Perioperative outcomes of cytoreductive surgery and perioperative intraperitoneal chemotherapy for non-appendiceal peritoneal carcinomatosis from a prospective database
    Tristan D Yan
    Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia 20010, USA
    J Surg Oncol 96:102-12. 2007
    ..An accurate assessment of perioperative outcomes is crucial for integration of this combined procedure into clinical practice...
  61. doi Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms
    Lana Bijelic
    Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia
    J Surg Oncol 98:295-9. 2008
    ..Despite its efficacy, recurrences remain a common problem...
  62. ncbi Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma--a prospective study of 70 consecutive cases
    Tristan D Yan
    Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, Suite 3900N, Washington, DC 20010, USA
    Ann Surg Oncol 14:515-25. 2007
    ....
  63. ncbi Tailgut cyst, an unusual cause of pseudomyxoma peritonei
    Luis Zappa
    Washington Cancer Institute, Washington, DC 20010, USA
    Tumori 95:514-7. 2009
    ..Retrorectal hamartoma, also known as tailgut cyst, is a rare tumor that arises from remnants of the embryonic postanal gut. The tumor occurs in the retrorectal space and may undergo malignant degeneration...
  64. ncbi Rectus abdominis muscle resection for abdominal wall recurrence of mucinous adenocarcinoma or peritoneal mesothelioma
    Tristan Yan
    Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
    Tumori 94:309-13. 2008
    ..With follow-up these entrapped cancer cells may progress as an abdominal wall recurrence of the disease process. Frequently, laparoscopy is the definitive diagnostic study which results in the abdominal wall cancer progression...
  65. doi Discordant histology of primary appendiceal adenocarcinoid neoplasms with peritoneal dissemination
    Tristan D Yan
    Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA
    Ann Surg Oncol 15:1440-6. 2008
    ..The objective of the present study was to quantitate these discordant histopathological findings and examine its clinical implication...
  66. ncbi Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process
    Faheez Mohamed
    The Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia 20010, USA
    J Surg Oncol 86:10-5. 2004
    ..Prognosis is best in patients with DPAM; unfortunately, some patients with DPAM succumb to a rapidly progressive disease process...
  67. ncbi Limited survival in the treatment of carcinomatosis from rectal cancer
    Rodrigo Gomes da Silva
    Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
    Dis Colon Rectum 48:2258-63. 2005
    ..An important task involves the clear description of the clinical features that influence prognosis in these patients...
  68. ncbi Comprehensive approach to advanced primary and recurrent ovarian cancer: a personal experience
    C Pablo Carmignani
    Washington Cancer Institute, 110 Irving Street NW, Washington, DC 20010, USA
    Expert Rev Anticancer Ther 4:477-87. 2004
    ..Patients that received a complete cytoreduction followed by perioperative intraperitoneal chemotherapy had an improved survival, with reasonable morbidity and mortality, as compared with those who received incomplete cytoreduction...
  69. ncbi Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumor
    Faheez Mohamed
    The Washington Cancer Institute, Washington Hospital Center, 106 Irving Street, NW, 3900N, Washington, DC 20010, USA
    Cancer Chemother Pharmacol 58:719-24. 2006
    ..Factors that may modify the thermal enhancement of melphalan were studied to optimize its clinical use with hyperthermia...
  70. ncbi Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience
    Paul H Sugarbaker
    Washington Cancer Institute, Washington, DC 20010, USA
    Semin Oncol 29:51-61. 2002
    ..A prolonged high quality of life is possible in the majority of patients...
  71. ncbi Computed tomographic characterization of malignant peritoneal mesothelioma
    Tristan Dongbo Yan
    Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington Hospital Center, DC 20010, USA
    Tumori 91:394-400. 2005
    ..Early recognition of this disease process with an orderly surgical approach will begin to optimize treatment...
  72. ncbi Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma
    Tristan D Yan
    Washington Hospital Center, Washington Cancer Institute, 106 Irving Street, NW, Suite 3900N, Washington, DC 20010, USA
    Ann Surg Oncol 14:41-9. 2007
    ....
  73. pmc Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy
    Kurt Van Der Speeten
    Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
    Curr Drug Discov Technol 6:72-81. 2009
    ..Timing of the chemotherapy as a planned part of the surgical procedure to maximize exposure of all peritoneal surfaces is crucial to success...
  74. ncbi Clinical presentation of peritoneal mesothelioma
    Yair I Z Acherman
    The Washington Cancer Institute, Washington Hospital Center, DC 20010, USA
    Tumori 89:269-73. 2003
    ..To describe the clinical presentation of peritoneal mesothelioma and its impact on survival...
  75. ncbi Intraperitoneal taxanes
    Faheez Mohamed
    Washington Cancer Institute, Washington Hospital Center, 110 Irving Street, NW, Washington, DC 20010, USA
    Surg Oncol Clin N Am 12:825-33. 2003
    ..Docetaxel requires further Phase II study, but its impressive activity with systemic administration may be optimized with intraperitoneal administration for the treatment of peritoneal surface malignancy...
  76. ncbi Cytoreduction of the small bowel surfaces
    Lana Bijelic
    Peritoneal Surface Malignancy Program, Washington Cancer Institute, Washington, DC, USA
    J Surg Oncol 97:176-9. 2008
  77. ncbi Utility of CEA and CA 19-9 tumor markers in diagnosis and prognostic assessment of mucinous epithelial cancers of the appendix
    C Pablo Carmignani
    Washington Cancer Institute, Washington, DC 20010, USA
    J Surg Oncol 87:162-6. 2004
    ..The use of these tumor markers in mucinous epithelial tumors of the appendix has not been previously determined...
  78. ncbi Safety monitoring of the coliseum technique for heated intraoperative intraperitoneal chemotherapy with mitomycin C
    O Anthony Stuart
    Washington Cancer Institute, Occupational and Environmental Medicine, Washington Hospital Center, Washington, DC 20010, USA
    Ann Surg Oncol 9:186-91. 2002
    ..The potential risk of this procedure to the operating room personnel has not been previously investigated...
  79. ncbi Adjuvant intraperitoneal chemotherapy: a review
    Paul H Sugarbaker
    Washington Cancer Institute, Washington, DC 20010, USA
    Recent Results Cancer Res 169:83-9. 2007
  80. ncbi Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma
    Carlos A Cerruto
    Department of Pathology, Washington Hospital Center, Washington, DC 20010, USA
    Arch Pathol Lab Med 130:1654-61. 2006
    ..Standardized treatments using cytoreductive surgery and perioperative intraperitoneal chemotherapy have extended this survival...
  81. ncbi Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions
    Faheez Mohamed
    The Washington Cancer Institute, Washington Hospital Center, 110 Irving Street, NW, Washington, DC 20010, USA
    Cancer Chemother Pharmacol 52:405-10. 2003
    ..5% dextrose peritoneal dialysis solution (peritoneal dialysis solution) and hetastarch (6% hydroxyethyl starch), a high molecular weight solution...
  82. ncbi Total anterior parietal peritonectomy
    Vinicius de Lima Vazquez
    Washington Cancer Institute, Washington, District of Columbia 20010, USA
    J Surg Oncol 83:261-3. 2003
  83. ncbi Cholecystectomy, lesser omentectomy, and stripping of the omental bursa: a peritonectomy procedure
    Vinicius de Lima Vazquez
    Washington Cancer Institute, Washington, DC 20010, USA
    J Surg Oncol 84:45-9. 2003
  84. ncbi Clinical perspective on desmoplastic small round-cell tumor
    Alberto Gil
    Washington Cancer Institute, Washington, DC 20010, USA
    Oncology 67:231-42. 2004
    ....
  85. ncbi Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan
    Paul H Sugarbaker
    Program in Peritoneal Surface Malignancy, Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA
    Cancer Chemother Pharmacol 59:151-5. 2007
    ..The use of heated intraoperative intraperitoneal melphalan may provide a pharmacokinetic and clinical advantage in this group of gastrointestinal cancer patients who cannot be made cancer-free with cytoreductive surgery...
  86. ncbi An evolving role of perioperative intraperitoneal chemotherapy after cytoreductive surgery for colorectal peritoneal carcinomatosis
    Tristan D Yan
    Ann Surg Oncol 14:2171-2. 2007
  87. ncbi Peritoneum as the first-line of defense in carcinomatosis
    Paul H Sugarbaker
    J Surg Oncol 95:93-6. 2007
  88. ncbi A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer
    Tristan D Yan
    Department of Surgery, University of New South Wales, St George Hospital, Sydney, NSW, Australia
    Ann Surg Oncol 14:2702-13. 2007
    ..The purpose of this systematic review and meta-analysis was to determine the effectiveness and safety of adjuvant intraperitoneal chemotherapy for patients with locally advanced resectable gastric cancer...
  89. ncbi [Treatment results of peritoneal dissemination from gastric cancer by neoadjuvant intraperitoneal-systemic chemotherapy]
    Yutaka Yonemura
    Peritoneal Dissemination Program, Shizuoka Cancer Center
    Gan To Kagaku Ryoho 31:1723-6. 2004
    ..Records of all patients who underwent CHPP and cytoreductive surgery from 1992 to 2001 were reviewed...
  90. ncbi van Ruth S, Bronkhorst MWGA, van Coeverden F, Zoetmulder FAN. Peritoneal benign cystic mesothelioma: a case report and review of literature. Eur J Surg Oncol 2002; 28(2): 192-5
    Kauimarz Sethna
    Eur J Surg Oncol 28:897. 2002
  91. ncbi Carcinomatosis--is cure an option?
    Paul H Sugarbaker
    J Clin Oncol 21:762-4. 2003
  92. pmc Incomplete cytoreduction in 174 patients with peritoneal carcinomatosis from appendiceal malignancy
    Olivier Glehen
    Surgical Department, Centre Hospitalo Universitaire Lyon Sud, Pierre Benite, France
    Ann Surg 240:278-85. 2004
    ..The aim of this study was to analyze the survival of patients with peritoneal dissemination of appendiceal malignancy having incomplete cytoreductive surgery...
  93. ncbi Initiation of a program in peritoneal surface malignancy
    Luis González Bayón
    Hospital Universitario Gregorio Maranon, C Dr Esquerdo, 46, 28007 Madrid, Spain
    Surg Oncol Clin N Am 12:741-53. 2003
    ..This manuscript provides a guide for implementation of this treatment strategy with a minimum of untoward events, reduced apprehension of medical and nursing colleagues, and a maximum benefit for patients...
  94. pmc Are there curative options to peritoneal carcinomatosis?
    Paul H Sugarbaker
    Ann Surg 242:748-50; author reply 750-1. 2005
  95. ncbi Local-regional approach to diffuse malignant peritoneal mesothelioma
    Paul H Sugarbaker
    Gastroenterol Clin Biol 31:780-1. 2007